Gerresheimer AG reacts to media reports Düsseldorf, June 17, 2025. Gerresheimer AG (ISIN: DE000A0LD6E6) reacts to media reports that KPS Capital Partners has decided against teaming up with Warburg Pincus on a potential public take-over offer for Gerresheimer AG. KPS Capital Partners has informed Gerresheimer AG upon request that they are still i [ … ]

Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority 2024: Progress on key strategic topics Long-term outlook remains positve thanks to the successfull transformation into a system and solution provider Dividend of EUR 0.04 per share Duesseldorf, June 5, 2025. The Annual General Meeting of Gerresheimer AG [ … ]

Gerresheimer Adjusts Guidance for Financial Year 2025 Preliminary results for Q2 2025: Low-single-digit organic revenue growth, adjusted EBITDA margin around 19% Continued subdued demand in the cosmetics market Temporary decline in demand for containment solutions for oral liquid medications New dividend proposal of 4% of share capital Long-te [ … ]

Gerresheimer AG: Adjustment of Guidance for 2025 Duesseldorf, June 2, 2025. Gerresheimer AG (ISIN: DE000A0LD6E6) is adjusting its guidance for 2025. This is due in particular to continuing subdued demand in the cosmetics market and a decline in demand for containment solutions for oral liquid medications, which the company considers to be tempora [ … ]

Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr New oxy-hybrid furnace reduces CO2e emissions by up to 40% Latest production technology and environmentally friendly cooling system Capacity expansion to support planned growth Total investment volume of approximately 100 million euros Duesseldo [ … ]

Gerresheimer: Bormioli Pharma boosts revenues and earnings Revenues +11.6%, Adjusted EBITDA +13.1% Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% Q1 significantly influenced by revenue shift in syringe business Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of [ … ]

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds Organic growth: revenue +2.9%, adjusted EBITDA +4.1% Destocking in vial business partially offset by strong growth in medical devices Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics Bormioli Pharma to boos [ … ]

Gerresheimer AG confirms discussions with private equity investors on potential takeover offer Düsseldorf, February 7, 2025 – The Executive Board of Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") reacts to press reports and confirms that Gerresheimer is in early-stage discussions with private equity investors who have expressed, on an infor [ … ]